Investors

Publications and Posters

Posters

Aridis Pharmaceuticals’ COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-COV2 Delta Variant
Safety and Efficacy of Salvecin (AR-301), a Human Monoclonal Antibody, in Patients with Sever Pneumonia Caused by S. aureus, a Phase 2 Study

Publications

Investor Presentation
Analysts Fireside Chat 2020

Fireside Chat Vimeo link

Aridis COVID-19 slides Cantor Fireside Chat

Cantor Fireside Video chat  link 

Aridis COVID-19 slides Maxim Conference
APEXTM Technology Presentation
Safety and tolerability of a single administration of AR 301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first in human trial
Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia,
Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia,
Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes,
Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers,

Tags: